ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jul 10, 2018
Twitter Working Backwards?
Image Source: Xiaobin LiuThe social media platform known for its tweets faced selling pressure after reports surfaced that it had removed 70 million fake accounts from its website. Social media is still a relatively young technology, and our top idea in the space remains the cash-rich Facebook.
Jul 5, 2018
In The News: Facebook, China and the Semiconductor Complex
Facebook gets a new Street high price target, while news ebbs and flows regarding US-China tech relations.
Jul 2, 2018
Financial Advisor (GOLD LEVEL) Publications
Learn about the gold level publications, the Dividend100, Ideas100, and DataScreener. These publications are updated and delivered via email to financial adviser (gold) levels members (subscribers of that plan) at the beginning of each calendar quarter.
Jun 29, 2018
Dividend Growth Still A Resilient Theme
Rising interest rates may pose headwinds to yield-sensitive dividend payers, but we think dividend growth investing remains a resilient theme. We’re big fans of the concept of yield-on-cost, but close attention to valuations, free cash flow generation and balance-sheet health will remain critical.
Jun 29, 2018
Dividend Increases/Decreases for the Week Ending June 29
Let's take a look at companies that raised/lowered their dividend this week.
Jun 28, 2018
Amazon: The Destroyer of Other Companies’ Profits
Image Source: Victor. Amazon is stepping into the pharmacy business with the purchase of online pharmacy start-up PillPack. The market is implying the move will prove to be more than just a headache for those operating in the drug store/pharmacy and drug-distributor complex. Whether the impact will be significantly material in the coming years remains to be seen, but it’s a big directional negative for impacted parties.
Jun 27, 2018
Roche Continues to Underwhelm
We like cutting-edge, novel therapies as they have a transformative impact on a small to mid-cap biotech as years of revenue growth could be in the cards. While new therapies are the life-blood of the research field, the impact of a new novel therapy on the growth prospects of a large cap is often muted, however. Such is the fate of Roche as it struggles to replace its mainstay oncology division with new patent-protected entities.
Jun 27, 2018
Restaurant Traffic Down, Chipotle Still a Favorite Idea
Image Source: Chipotle (page 89 of 160). In late April of this year, we added Chipotle to the simulated Best Ideas Newsletter portfolio. The high end of our fair value estimate is nearly $600.
Jun 26, 2018
General Electric Stripping Businesses, Dividend in Aggregate
Image source: GE investor presentation. Once a seemingly unshakable component of the Dow Jones Industrial Average and one of the most-recognizable industrial firms in the world, General Electric announced further divestiture plans of its sprawling portfolio of businesses. More changes are in store for its dividend as well.
Jun 26, 2018
Eli Lilly Looks to Bolster Its Presence in Oncology
We are becoming increasingly impressed with Eli Lilly as the company boasts an enviable stable of new products that should power the company well into the next decade. Lilly is through the bulk of its patent trough, in our view, and its pipeline should set the company up for years of potentially uninterrupted revenue growth. Shares are not necessarily cheap, however.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.